# Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma

> **NCT05188118** · EARLY_PHASE1 · RECRUITING · sponsor: **Icahn School of Medicine at Mount Sinai** · enrollment: 20 (estimated)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **DRUG:** Cabozantinib
- **DRUG:** Ipilimumab
- **DRUG:** Nivolumab
- **DRUG:** Lenvatinib
- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT05188118
- **Lead sponsor:** Icahn School of Medicine at Mount Sinai
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-15
- **Primary completion:** 2026-09
- **Final completion:** 2026-12
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05188118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05188118, "Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05188118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*